Opinion|Videos|November 14, 2023
Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma
Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Trotabresib Plus CRT Fails to Improve PFS in Newly Diagnosed Glioblastoma
4
Can AI Fix Clinical Trial Access in Oncology? Dr. Arturo Loaiza-Bonilla Built the Answer With the Data to Back It.
5